Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 292, Issue 2, 2000, Pages 810-816

  Benincosa, Lisa J ^b   Chow, Fung Sing ^a,b   Tobia, Leeann P ^b   Kwok, Deborah C ^b   Davis, Charles B ^b   Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9; MONOCLONAL ANTIBODY; SB 249417; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; MALE; MONKEY; NONHUMAN; PHARMACODYNAMICS; PLASMA CLEARANCE; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR IX; HUMANS; IMMUNOGLOBULIN G; LIGANDS; MACACA FASCICULARIS; MALE; PARTIAL THROMBOPLASTIN TIME; PROTEIN BINDING; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 0033968587     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Allen GD (1990) MODFIT: A pharmacokinetics computer program. Biopharm Drug Dispos 11:477-498.
2. Brandt JT, Arkin CF, Bovill EG, Rock WA and Triplett DA (1990) Evaluation of aPTT reagent sensitivity to Factor IX and Factor IX assay performance. Arch Pathol Lab Med 114:135-141.
3. Davie EW (1995) Biochemical and molecular aspects of the coagulation cascade. Thromb Haemostasis 74:1-6.
4. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
5. Davis CB and Bugelski PJ (1998) Subcutaneous bioavailability of a PRIMATIZED IgG1 anti-human CD4 monoclonal antibody is dose dependent in transgenic mice bearing human CD4. Drug Delivery 5:95-100.
6. Davis CB, Garver EM, Kwok DC and Urbanski JJ ( 1996) Disposition of metabolically radiolabeled CD9.1 - a Macaque-human chimeric anti-human CD4 monoclonal antibody - in transgenic mice bearing human CD4. Drug Metab Dispos 24:1032-1037.
7. Davis CB, Tobia LP, Kwok DC, Oishi CM, Kheterpal N, Hepburn TW, Benincosa LJ, Chow FS and Jusko WJ (1999) Accumulation of antibody-target complexes and the pharmacodynamics of clotting after single intravenous administration of humanized anti-Factor IX monoclonal antibody to rats. Drug Delivery 6:171-179.
8. Davis CB, Hepburn TW, Urbanski JJ, Kwok DC, Hart TK, Herzyk DJ, Demuth SG, Leland M and Rhodes GR (1995) Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19. Drug Metab Dispos 23:1028-1036.
9. D'Argenio DZ and Schumitzky A (1979) A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 9:115-134.
10. Feuerstein GZ, Patel A, Toomey JR, Bugelski P, Nichols AJ, Church WR, Valocik R, Koster P, Baker A and Blackburn MN (1999) Anti-thrombotic efficacy of a novel murine anti-human factor IX antibody in rats. Arteriosclerosis Thromb Vasc Biol 19:2554-2562.
11. Gibaldi M and Perrier D (1982) Pharmacokinetics, 2nd ed., p 86, Marcel Dekker, New York.
12. Gobburu JVS, Tenhoor C, Rogge MC, Frazier DE Jr, Thomas D, Benjamin C, Hess M and Jusko WJ (1998) Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD4 ligand) suppression of an immune response in monkeys. J Pharmacol Exp Ther 286:925-930.
13. Hamilton RG and Morrison SL (1993) Epitope mapping of human immunoglobulin-specific murine monoclonal antibodies with domain-switched deleted and point-mutated chimeric antibodies. J Immunol Methods 158:107-122.
14. Kessler CM (1991) The pharmacology of aspirin, heparin, coumarin, and thrombolytic agents: implications for therapeutic use in cardiopulmonary disease. Chest 99:97S-112S.
15. Mannucci PM (1994) Mechanisms, markers and management of coagulation activation. Brit Med Bull 50:851-870.
16. Mould DR, Davis CB, Minthorn EA, Kwok DC, Elliott MJ, Luggen ME and Totoritis MC (1999) A population PK/PD analysis of single doses of clenoliximab in rheumatoid arthritis patients. Clin Pharmacol Ther 66:246-257.
17. Rodvold KA and Friedenberg WR (1989): Coagulation disorders, in Pharmacotherapy: A Pathophysiologic Approach (DiPiro JT, Talbert RL, Hayes PE, Yee GC and Posey LM eds) p 1003, Elsevier, New York.
18. Samama MM, Bara L and Gouin-Thibault I (1996) New data on the pharmacology of heparin and low molecular weight heparins. Drugs 52:S7:8-15.
19. Shand DG, Desjardins RE, Bjornsson TD, Hamill SC and Princhett ELC (1981) The method of separate exponentials: A simple aid to devising intravenous drug-loading regimens. Clin Pharmacol Ther 29:542-547.
20. Schrör K (1995) Antiplatelet drugs: A comparative review. Drugs 50:7-28.
21. Zia-Amirhosseini P, Minthorn E, Benincosa LJ, Hart TK, Hottenstein CS, Tobia LP and Davis CB (1999) Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys. J Pharmacol Exp Ther 291:1060-1067.